Skip to main content
SpringerLink
Log in

Epirubicin

Clinical Pharmacology and Dose-Effect Relationship

  • Published:
Drugs Aims and scope Submit manuscript

Summary

The pharmacokinetic properties of epirubicin are characterised by a triphasic plasma clearance, with half-lives for the initial (α), intermediate (β) and terminal (γ) elimination phases of approximately 3 minutes, 1 hour and 30 hours, respectively. These values are similar to or slightly shorter than the corresponding half-lives of doxorubicin. The total plasma clearance of epirubicin is approximately 50 L/h/m2, which is almost 2-fold higher than that of doxorubicin. This difference is mainly due to the relatively high volume of distribution of epirubicin, and the unique glucuronidation metabolic pathway of epirubicin and epirubicinol, which is not available to doxorubicin or doxorubicinol. Glucuronide metabolites of epirubicin and epirubicinol are not active per se, but could divert epirubicin from free radical formation, which may induce cardiotoxic effects. This may explain, at least in part, the lower cardiotoxicity of this new anthracycline relative to that of the parent compound. There is a linear relationship between the dose administered and area under the plasma concentration-time curve (AUC) values of both unchanged drug and metabolites, so that the total plasma clearance of epirubicin is constant with epirubicin doses ranging from 40 to 140 mg/m2. No variation in total plasma clearance as a function of age in the range of 31 to 74 years has been observed, and this parameter is unaffected by subsequent courses of treatment. Hepatic dysfunction causes an increase in the terminal elimination half-life of epirubicin, which is well correlated with serum bilirubin levels and which necessitates a reduction in epirubicin dosage.

Epirubicin is responsible for a dose-dependent neutropenia, which is clearly related to drug exposure as established in pharmacodynamic studies. The maximum tolerated dose (MTD) of epirubicin was first established to be approximately 90 mg/m2 but this was re-examined recently and is now deemed to be approximately 150 mg/m2, which is about 2-fold higher than the MTD of doxorubicin. Cumulative cardiac toxicity occurs for both epirubicin and doxorubicin, but the dose ratio for equal risk is about 1.8 in favour of epirubicin (500 to 550 mg/m2 for doxorubicin vs 900 to 1000 mg/m2 for epirubicin). Consequently, there is not a higher risk of developing cardiotoxicity after administration of high dose epirubicin, since this adverse effect is associated with total cumulative anthracycline dose. In several controlled trials, epirubicin exhibited the same anticancer activity as doxorubicin when administered at equimolar doses to patients with advanced breast cancer. When used in high dose regimens, either as a single agent or in combination with other cytotoxic drugs, response rates were significantly increased in most studies, with acceptable immediate toxicity and no increase in cardiac risk. Together, these factors justify the use of epirubicin as adjuvant therapy in patients with breast cancer of poor prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Arcamone F, Penco S, Vigevani A. Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone. Journal of Medicinal Chemistry 18: 703–707, 1975

    Article  PubMed  CAS  Google Scholar 

  • Bertazzoli C, Rovero C, Ballerini L, Lux B, Balconi F, et al. Experimental systemic toxicology of 4′-epidoxorubicin, a new less cardiotoxic anthracycline antitumor agent. Toxicology and Applied Pharmacology 79: 412–422, 1985

    Article  PubMed  CAS  Google Scholar 

  • Bezwoda WR, Seymour L, Ariad S, Vorobiof D. High-dose 4′-epiadriamycin as primary treatment for advanced breast cancer. Abstract 72. Proceedings of the American Society for Clinical Oncology 10: 49, 1991

    Google Scholar 

  • Blackstein M, Eisenhauer EA, Wierzbicki R, Yoshida S. Epirubicin in extensive small cell lung cancer: a phase II study in previously untreated patients: a National Cancer Institute of Canada Clinical Trials Group Study. Journal of Clinical Oncology 8: 385–389, 1990

    PubMed  CAS  Google Scholar 

  • Brambilla C, Rossi A, Bonfante V, Ferrari L, Villani F, et al. Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treatment Reports 70: 261–266, 1986

    PubMed  CAS  Google Scholar 

  • Camaggi CM, Strocchi E, Tamassia V, Martoni A, Giovannini M, et al. Pharmacokinetic studies of 4′-epidoxorubicin in cancer patients with normal and impaired renal function and with hepatic metastases. Cancer Treatment Reports 66: 1819–1824, 1982

    PubMed  CAS  Google Scholar 

  • Camaggi CM, Strocchi E, Martoni A, Angelelli B, Comparsi R, et al. Epirubicin plasma and blood pharmacokinetics after single iv bolus in advanced cancer patients. Drugs Under Experimental and Clinical Research 11: 285–294, 1985

    PubMed  CAS  Google Scholar 

  • Camaggi CM, Strocchi E, Comparsi R, Testoni F, Angelelli B, et al. Biliary excretion and pharmacokinetics of 4′-epidoxorubicin in advanced cancer patients. Cancer Chemotherapy and Pharmacology 18: 47–50, 1986

    Article  PubMed  CAS  Google Scholar 

  • Camaggi CM, Comparsi R, Strocchi E, Testoni F, Angelelli B, et al. Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. Cancer Chemotherapy and Pharmacology 21: 221–228, 1988

    PubMed  CAS  Google Scholar 

  • Carmo-Pereira J, Costa FO, Miles DW, Henriques E, Richards MA. High-dose epirubicin as primary chemotherapy in advanced breast carcinoma: a phase II study. Cancer Chemotherapy and Pharmacology 27: 394–396, 1991

    Article  PubMed  CAS  Google Scholar 

  • Casazza AM. Experimental evaluation of anthracycline analogs. Cancer Treatment Reports 63: 835–844, 1979

    PubMed  CAS  Google Scholar 

  • Case Jr DC, Ervin TJ, Ganes R, Sonneborn HL, Paul JD, et al. Phase I–II study of epirubicin in multiple myeloma. Cancer Research 48: 6246–6248, 1988

    PubMed  Google Scholar 

  • Case Jr DC, Ganes R, Ervin TJ, Boyd MA, Oldham FB. Phase I-II trial of high-dose epirubicin in patients with lymphoma. Cancer Research 47: 6393–6396, 1987

    PubMed  Google Scholar 

  • de Vries EGE, Greidanus J, Mulder NH, Nieweg MB, Postmus PE, et al. A phase I and pharmacokinetic study with 21-day continuous infusion of epirubicin. Journal of Clinical Oncology 5: 1445–1451, 1987

    PubMed  Google Scholar 

  • Eksborg S, Stendhal U, Lönroth U. Comparative pharmacokinetic study of adriamycin and 4′-epiadriamycin after their simultaneous intravenous administration. European Journal of Clinical Pharmacology 30: 629–631, 1986a

    Article  PubMed  CAS  Google Scholar 

  • Eksborg S, Andersson M, Domellöf L, Lönroth U. A pharmacokinetic study of adriamycin and 4′-epiadriamycin after simultaneous intraarterial liver administration. Medical Oncology and Tumor Pharmacotherapy 3: 1005–1010, 1986b

    Google Scholar 

  • Focan C, Closon MT, Andrien JM, Dicato M, Driesschaert P, et al. Dose-response relationship with epirubicin as neoadjuvant chemotherapy for advanced breast cancer. End results of a prospective randomized trial. Abstract. IIIrd International Congress of Neoadjuvant Chemotherapy, Paris, February 6–9, 1991

    Google Scholar 

  • Fountzilas G, Skarlos D, Pavlidis NA, Makrantonakis P, Tsavaris N, et al. High-dose epirubicin as a single agent in the treatment of patients with advanced breast cancer. Tumori 77: 232–236, 1991

    PubMed  CAS  Google Scholar 

  • French Epirubicin Study Group. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin. Journal of Clinical Oncology 6: 679–688, 1988

    Google Scholar 

  • French Epirubicin Study Group. A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. Journal of Clinical Oncology 9: 305–312, 1991

    Google Scholar 

  • Ganzina F. 4′-epidoxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. Cancer Treatment Reviews 10: 1–22, 1983

    Article  PubMed  CAS  Google Scholar 

  • Gasparini G, Dal Fior S, Panizzoni GA, Favretto S, Pozza F. Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial. American Journal of Clinical Oncology 14: 38–44, 1991

    Article  PubMed  CAS  Google Scholar 

  • Habeshaw T, Paul J, Jones R, Stallard S, Stewart M, et al. Epirubicin at two dose level with prednisolone as treatment for advanced breast cancer: the results of a randomized trial. Journal of Clinical Oncology 9: 295–304, 1991

    PubMed  CAS  Google Scholar 

  • Hérait P, Poutignat N, Marty M, Bugat R. Early assessment of a new anticancer drug analogue. Are the historical comparisons obsolete? The French experience with pirarubicin. European Journal of Cancer 28: 1670–1676, 1992

    Article  Google Scholar 

  • Hill BT, Whelan RDH. A comparison of the lethal and kinetic effects of doxorubicin and 4′-epidoxorubicin in vitro. Tumori 68: 29–37, 1982

    PubMed  CAS  Google Scholar 

  • Hortobágyi GN. The importance of dose-response in cytotoxic therapy for breast cancer. In Henderson IC, Borden EC (Eds) Advances in breast cancer treatment, pp. 47–62, Mediscript, London, 1990

    Google Scholar 

  • Hortobágyi GN, Yap HY, Kau SW, Fraschini G, Ewer MS, et al. A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. American Journal of Clinical Oncology 12: 57–62, 1989

    Article  PubMed  Google Scholar 

  • Hryniuk WM, Bush M. The importance of dose intensity in chemotherapy of metastatic breast cancer. Journal of Clinical Oncology 2: 1281–1288, 1984

    PubMed  CAS  Google Scholar 

  • Hryniuk WM, Figueredo A, Goodyear M. Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Journal of Oncology 14: 3–11, 1987

    CAS  Google Scholar 

  • Hu OYP, Chang SP, Jame JM, Chen KY. Pharmacokinetic and pharmacodynamic studies with 4′-epidoxorubicin in nasopharyngeal carcinoma patients. Cancer Chemotherapy and Pharmacology 24: 332–337, 1989

    Article  PubMed  CAS  Google Scholar 

  • Italian Multicenter Breast Study With Epirubicin. Phase III randomized study of fluorouracil, epirubicin and cyclophosphamide vs fluorouracil, doxorubicin and cyclophosphamide in advanced breast cancer. An Italian multicenter trial. Journal of Clinical Oncology 6: 976–982, 1988

    Google Scholar 

  • Jain K, Casper ES, Geller NL, Hakes TB, Kaufman RJ, et al. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. Journal of Clinical Oncology 3: 818–826, 1985

    PubMed  CAS  Google Scholar 

  • Jakobsen P, Steiness E, Bastholt L, Dalmark M, Lorenzen A, et al. Multiple dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer. Cancer Chemotherapy and Pharmacology 28: 63–68, 1991a

    Article  PubMed  CAS  Google Scholar 

  • Jakobsen P, Bastholt L, Dalmark M, Pfeiffer P, Petersen D, et al. A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood sample measurement. Cancer Chemotherapy and Pharmacology 28: 465–469, 1991b

    Article  PubMed  CAS  Google Scholar 

  • Johnson JR, Morgan DAL. A phase II evaluation of 4′-epidoxorubicin in small cell lung cancer. Abstract. British Journal of Cancer 56: 871, 1987

    Google Scholar 

  • Jones RB, Holland JF, Bhardwaj J, Norton L, Wilfinger C, et al. A phase I-II study of intensive dose adriamycin for advanced breast cancer. Journal of Clinical Oncology 5: 172–177, 1987

    PubMed  CAS  Google Scholar 

  • Joss RA, Hansen HH, Hansen M, Renards J, Rosenberg M. Phase II trial of epirubicin in advanced squamous, adeno- and large cell carcinoma of the lung. European Journal of Cancer and Clinical Oncology 26: 495–499, 1984

    Article  Google Scholar 

  • Loveless H, Arena E, Felsted RL, Bachur NR. Comparative mammalian metabolism of adriamycin and daunomycin. Cancer Research 38: 593–598, 1978

    PubMed  CAS  Google Scholar 

  • Marschner N, Nagel GA, Beyer JH, Adler M, Ammon A. High-dose epirubicin in combination with cyclophosphamide in advanced breast cancer: final results of a dose-finding study and phase II trial. Onkologie 13: 272–278, 1990

    Article  PubMed  CAS  Google Scholar 

  • Martin M, Lluch A, Gillem V, Jimeno J, Aranda E, et al. High-dose epirubicin + cyclophosphamide as primary chemotherapy in stage III a/b breast cancer. Abstract 323. European Journal of Cancer 27: S58, 1991

    Google Scholar 

  • Martini A, Moro E, Pacciarini MA, Tamassia V, Natale N, et al. Crossover study of pharmacokinetics and haematological toxicity of 4′-epidoxorubicin in cancer patients. International Journal of Clinical and Pharmacological Research 4: 231–238, 1984

    CAS  Google Scholar 

  • Mouridsen HT. New cytotoxic drugs in treatment of breast cancer. Acta Oncologica 29: 343–347, 1990

    Article  PubMed  CAS  Google Scholar 

  • Mouridsen HT, Alfthan C, Bastholt L, Bergh J, Dalmark M, et al. Current status of epirubicin in the treatment of solid tumors. Acta Oncologica 29: 257–285, 1990

    Article  PubMed  CAS  Google Scholar 

  • Mross K, Maessen P, van der Vijgh WJF, Bogdanowicz CZ, Kurth KH, et al. Absorption of epidoxorubicin after intravesical administration in patients with in situ transitional cell carcinoma of the bladder. European Journal of Cancer and Clinical Oncology 23: 505–508, 1987

    Article  CAS  Google Scholar 

  • Mross K, Maessen P, van der Vijgh WJF, Gall H, Boven E, et al. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in human. Journal of Clinical Oncology 6: 517–526, 1988

    PubMed  CAS  Google Scholar 

  • Neidhart JP. Hematopoietic colony-stimulating factors. Uses in combination with standard chemotherapeutic regimens and in support of dose intensification. Cancer 70: 913–920, 1992

    PubMed  CAS  Google Scholar 

  • Neri B, Pacini P, Bartalucci S, Moroni F, Menchi I, et al. Epirubicin high-dose therapy in advanced breast cancer: preliminary clinical data. Epirubicin as a single agent in breast cancer. International Journal of Clinical Pharmacology, Therapy and Toxicology 27: 388–391, 1989

    CAS  Google Scholar 

  • Neri B, Pacini P, Cappellini M, Algeri R, Rinaldini M, et al. Conventional vs high-dose epirubicin as single agent in advanced breast cancer. Abstract 132. Proceedings of the American Society of Clinical Oncology 10: 64, 1991

    Google Scholar 

  • O’Bryan RM, Baker LH, Gottlieb JE, Rivkin SE, Balcerzak SP, et al. Dose-response evaluation of adriamycin in human neoplasia. Cancer 39: 1940–1948, 1977

    Article  PubMed  Google Scholar 

  • Pannuti F, Camaggi CM, Strocchi E, Comparsi R, Rossi AD, et al. Intrahepatic arterial administration of 4′-epidoxorubicin in advanced cancer patients. A pharmacokinetic study. European Journal of Cancer and Clinical Oncology 22: 1309–1314, 1986

    Article  CAS  Google Scholar 

  • Piccart M, van der Schueren E, Bruningx P, Kerger J, Kennes C, et al. High-dose intensity chemotherapy with epiadriamycin, cyclophosphamide and r-met HuG-CSF in breast cancer patients. Abstract 308. European Journal of Cancer 27: S56, 1991

    Google Scholar 

  • Plumbridge TW, Brown JR. Studies on the mode of interaction of 4′-epiadriamycin and 4-demethoxydaunomycin with DNA. Biochemical Pharmacology 27: 1881, 1978

    Article  PubMed  CAS  Google Scholar 

  • Praga C, Trave F, Petroccione A. Anthracycline-induced cardiotoxicity and its relevance in cancer treatment. In Nimmo WS, Tucker GT (Eds) Clinical measurement in drug evaluation, pp. 131–192, Wolfe, London, 1991

    Google Scholar 

  • Robert J, Bui NB. Pharmacokinetics and metabolism of epirubicin administered as i.v. bolus and 48-h infusion in patients with advanced soft-tissue sarcoma. Annals of Oncology 3: 651–656, 1992

    PubMed  CAS  Google Scholar 

  • Robert J, David M, Granger C. Metabolism of epirubicin to glucuronides: relationship to the pharmacodynamics of the drug. Cancer Chemotherapy and Pharmacology 27: 147–150, 1990

    Article  PubMed  CAS  Google Scholar 

  • Robert J, Vrignaud P, Nguyen-Ngoc T, Iliadis A, Mauriac L, et al. Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer. Cancer Treatment Reports 69: 633–640, 1985

    PubMed  CAS  Google Scholar 

  • Rowe JM, Rapoport AP. Hemopoietic growth factors: a review. Journal of Clinical Pharmacology 32: 486–501, 1992

    Article  PubMed  CAS  Google Scholar 

  • Schott B, Robert J. Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture. Biochemical Pharmacology 38: 4069–4074, 1989

    Article  PubMed  CAS  Google Scholar 

  • Sledge GW, Roth BJ, Munshi N, Baughman C, Einhorn LH, et al. High-dose epirubicin as initial therapy for advanced breast cancer. Abstract 166. Proceedings of the American Society for Clinical Oncology 11: 85, 1992

    Google Scholar 

  • Strocchi E, Camaggi CM, Rossi AD, Angelelli B, Comparsi R, et al. Epirubicin pharmacokinetics after intrahepatic arterial and intraperitoneal administration. Drugs Under Experimental and Clinical Research 11: 295–302, 1985

    PubMed  CAS  Google Scholar 

  • Tjuljandin SA, Drog RG, Sobol MM, Watson DM, Sheridan WP, et al. Pharmacokinetics and toxicity of two schedules of high dose epirubicin. Cancer Research 50: 5095–5101, 1990

    PubMed  CAS  Google Scholar 

  • Vrignaud P, Eghbali H, Hoerni B, Iliadis A, Robert J. Pharmacokinetics and metabolism of epirubicin during repetitive courses of administration in Hodgkin’s patients. European Journal of Cancer and Clinical Oncology 21: 1307–1313, 1985

    Article  CAS  Google Scholar 

  • Walde D, Bettello P. A single community centre phase II trial of high dose epirubicin in stage IV breast cancer. Abstract 76. Proceedings of the American Society for Clinical Oncology 10: 50, 1991

    Google Scholar 

  • Weenen H, Lankelma J, Penders PGM, McVie JG, Ten Bokkel Huinink WW, et al. Pharmacokinetics of 4′-epidoxorubicin in man. Investigational New Drugs 1: 59–64, 1983

    Article  PubMed  CAS  Google Scholar 

  • Weenen H, van Maanen JMS, de Planque MM, McVie JG, Pinedo HM. Metabolism of 4′-modified analogs of doxorubicin. Unique glucuronidation pathway for 4′-epidoxorubicin. European Journal of Cancer and Clinical Oncology 20: 919–926, 1984

    Article  CAS  Google Scholar 

  • Wheeler RH, Ensminger WD, Thrall SH, Anderson JL. High-dose doxorubicin: an exploration of the dose-response curve in human neoplasia. Cancer Treatment Reports 66: 493–498, 1982

    PubMed  CAS  Google Scholar 

  • Wils J, Utama I, Sala L, Smeets J, Riva A. Phase II study of high-dose epirubicin in non-small cell lung cancer. European Journal of Cancer 26: 1140–1141, 1990

    Article  PubMed  CAS  Google Scholar 

  • Workman P. Infusional anthracyclines: Is slow better? If so, why? Annals of Oncology 3: 591–594, 1992

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fondation Bergonié, 180 rue de Saint-Genès, 33076, Bordeaux, Cedex, France

    Jacques Robert

Authors
  1. Jacques Robert
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Robert, J. Epirubicin. Drugs 45 (Suppl 2), 20–30 (1993). https://doi.org/10.2165/00003495-199300452-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199300452-00005

Keywords

Search

Navigation